558

Depression, Pain, and Physical Symptoms
[ CME Expired ]

 

Depression, Pain, and Physical Symptoms
[ CME Expired ]

This activity is part of the Depression Unit, which is supported by educational grants from Eli Lilly and Company and Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Evidence-Based Treatment Paradigms for Depressed Patients With Pain and Physical Symptoms

David A. Fishbain, MD

Departments of Psychiatry and Behavioral Sciences, Neurological Surgery, and Anesthesiology, University of Miami Miller School of Medicine, Miami, Fla

Antidepressants as Analgesics

Since the 1970s, numerous clinical studies have explored the effects of antidepressants on painful physical symptoms to answer 2 main questions: Do antidepressants alleviate pain? If so, are the analgesic properties independent from the improvement in depression? Unfortunately, early studies addressing these questions were riddled with methodological problems, such as small sample sizes, poor study designs, and inconsistent patient populations. Therefore, these studies produced conflicting results.

Not until the early 1990s did an answer materialize concerning the role of antidepressant treatment in alleviating pain. Two meta-analyses of controlled studies—one of 39 trials1 and one of 67 trials2—determined that antidepressants did indeed alleviate general pain. However, these meta-analyses did not distinguish results of neuropathic from nonneuropathic pain. A subsequent meta-analysis3 of 21 placebo-controlled trials did find that antidepressants were effective analgesics for neuropathic pain (AV 1AV 1), including diabetic neuropathy, postherpetic neuralgia, atypical facial pain, and central pain.

Fishbain et al.4 found that antidepressants were effective analgesics for psychogenic pain and somatoform pain disorder, with a large effect size (mean = 0.48). This meta-analysis4 of 11 controlled studies raised the issue of the validity of the diagnosis of psychogenic pain and somatoform pain disorder because analgesics, in general, should not have an effect on psychogenic or somatoform pain disorder above that of the placebo response.

In addition to neuropathic pain and psychogenic/somatoform pain, antidepressants may be efficacious for chronic lower back pain and pain associated with osteoarthritis, rheumatoid arthritis, and healing ulcers.5 Evidence5–7 also indicates that antidepressants improve pain as well as various other somatic symptoms, such as sleep, in patients with fibromyalgia.

Single-Action Vs Dual-Action Antidepressants

Dual-action agents, that is, medications that inhibit both serotonin and norepinephrine, may have greater antinociceptive effects than antidepressants with selective serotonergic or noradrenergic effects (AV 2AV 2).8 For example, an evidence-based structured review9 of neuropathic pain animal models and antidepressant treatment studies found an analgesic effect in 100% of the trials with serotonin-norepinephrine reuptake inhibitors (SNRIs), 88.9% of trials with noradrenergic antidepressants, and 14.3% of trials with serotonergic antidepressants. Further, meta-analyses5,6,10,11 of human studies have suggested that dual-action antidepressants have a more consistent analgesic effect than serotonergic antidepressants for some types of pain.

Lower back pain. A review11 of lower back pain studies reported that selective serotonin reuptake inhibitors (SSRIs) were not effective in the 3 trials with these agents, whereas tricyclic or tetracyclic antidepressants that also inhibit noradrenergic reuptake produced improvement on at least 1 outcome measure in 4 of the 5 trials examined.

Neuropathic pain. Duloxetine, an SNRI, is the first antidepressant approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetic peripheral neuropathic pain. In a large study (N=457),12 duloxetine demonstrated efficacy for improving pain within 1 week of treatment initiation compared with placebo (AV 3AV 3).

Rowbotham et al.13 found that, at higher dosages, venlafaxine, another SNRI, was effective for neuropathic pain (AV 4 AV 4). Because this effect may be dose related, separation from placebo did not occur until week 3, after doses had been titrated to therapeutic levels.

Fibromyalgic pain. Duloxetine has also been approved by the FDA for the treatment of fibromyalgia. Milnacipran and venlafaxine, other SNRIs, have also been studied for efficacy in fibromyalgia treatment. Milnacipran14 and duloxetine15,16 have shown efficacy in decreasing fibromyalgia pain (particularly in women) in large controlled trials, but the same level of evidence does not exist for venlafaxine.

Individual studies of SSRIs in fibromyalgia have shown some evidence of efficacy for pain, but results have been mixed. Arnold et al.17 found that, compared with placebo, fluoxetine significantly improved Fibromyalgia Impact Questionnaire total scores (p = .005), pain scores (p = .002), and McGill Pain Questionnaire scores (p = .01). However, no significant differences were found between fluoxetine and placebo on tender point counts and myalgic scores. In 2 trials,18,19 citalopram showed no significant advantage over placebo in patients with fibromyalgia. This evidence suggests that dual-action antidepressants, including tricyclics and SNRIs, have a more consistent analgesic effect than SSRIs.

More

Antidepressant comparison. Head-to-head trials of SNRIs and SSRIs would be ideal for determining the efficacy of these agents in treating pain, but no such trials have yet been conducted. To circumvent the problem of lacking head-to-head trials, the number-needed-to-treat (NNT) concept can be used. The NNT is the number of patients who would have to be treated with an agent to obtain 1 patient with ≥ 50% response. The best NNT is 1, because that means a response was obtained in each patient treated. For various forms of neuropathic pain, dual-action tricyclics have the lowest NNT at 2.2; noradrenergic tricyclics have an NNT of 2.5; SNRIs have NNTs between 4.6 and 5.7; and SSRIs have the highest NNT at 6.8.20,21

Independence of Analgesic Effect

Are the analgesic properties of antidepressants due to their antidepressant effects, or is the analgesic effect an independent function? Goldstein et al.12 found that the direct effect of 120 mg/day of duloxetine on diabetic peripheral neuropathic pain accounted for 88.6% of the total pain improvement, whereas improvement in depression accounted for only 11.4% of pain improvement.

Fishbain et al.22 conducted a post-hoc analysis of 6 placebo-controlled trials of duloxetine in 900 patients with major depressive disorder and diabetic peripheral neuropathy, measuring pain with the Visual Analog Scale. The researchers theorized that, if the analgesic response was dependent on the antidepressant response, then the antidepressant response should occur first. However, in the study, the median time to analgesic effect occurred earlier (28 days to response) than the antidepressant effect (42 days to response). In addition, no correlation was found between the analgesic response curve and the antidepressant response curve, which indicates that the analgesic effect is independent of the antidepressant effect and vice versa.

Milnacipran14 and venlafaxine23 also appear to have an analgesic effect independent of the antidepressant effect, but evidence from large controlled trials for venlafaxine is lacking.

Conclusion

The treatment plan for patients with depression associated with pain should be aggressive, with the goal of remission. Evidence suggests that some antidepressants have analgesic properties, such as dual-action antidepressants, and these agents may be the best treatment for many patients with depression and co-occurring pain.

Drug Names

citalopram (Celexa and others), duloxetine (Cymbalta), fluoxetine (Prozac and others), venlafaxine (Effexor and others)

Take the online posttest.

References

  1. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992;49:205–219
  2. Philipp M, Fickinger M. Psychotropic drugs in the management of chronic pain syndromes. Pharmacopsychiatry 1993;26:221–234
  3. McQuay HJ, Tramèr M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217–227
  4. Fishbain DA, Cutler RB, Rosomoff HL, et al. Do antidepressants have an analgesic effect in psychogenic pain and somatoform disorder? a meta-analysis. Psychosom Med 1998;60:503–509
  5. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 2000;32:305–316
  6. O'Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999;48:980–990
  7. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 2000;41:104–113
  8. Glazer WM, Jain R, Arnold LM. Pain and the brain. J Clin Psychiatry 2008;69:e25. Available at: http://www.cmeinstitute.com/dvd_series/pain_and_the_brain/. Accessed Oct 22, 2008
  9. Fishbain DA, Cutler RB, Rosomoff HL, et al. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med 2000;1:310–316
  10. Lynch M. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001;26:30–36
  11. Staiger TO, Gaster B, Sullivan MD, et al. Systematic review of antidepressants in the treatment of chronic low back pain. Spine 2003;28:2540–2545
  12. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109–118
  13. Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110:697–706
  14. Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19(suppl 1):S27–S35
  15. Arnold LM, Lu Y, Crofford LJ, et al, for the Duloxetine Fibromyalgia Trial Group. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974–2984
  16. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5–15
  17. Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;15:191–197
  18. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4:27–35
  19. Nørregaard J, Volkmann H, Danneskiold-Samsøe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995;61:445–449
  20. Sindrup SH, Otto M, Finnerup NB, et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharamcol Toxicol 2005;96:399–409
  21. Sultan A, Gaskell H, Derry S, et al. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol 2008;8:29
  22. Fishbain DA, Detke MJ, Wernicke J, et al. The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder. Curr Med Res Opin 2008;24:3105–3115
  23. Sayar K, Aksu G, Ak I, et al. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003;37:1561–1565